Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 September;48(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 September;48(3):237-42

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 September;48(3):237-42

    ORIGINAL ARTICLES

Comparative evaluation of two methods to assay thyroglobulin serum concentrations in patients with differentiated thyroid carcinomas

Ferrari L. 1, Seregni E. 1, Aliberti G. 1, Martinetti A. 1, Pallotti F. 1, Villano C. 1, Lucignani G. 2, Bombardieri E. 1

1 Nuclear Medicine Division Radioisotope Laboratory Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
2 Institute of Radiological Sciences University of Milan, Unit of Molecular Imaging Division of Radiation Therapy European Institute of Oncology, Milan, Italy

Aim. This ­study was ­aimed at the com­par­a­tive assess­ment of the ana­lyt­i­cal and clin­i­cal per­for­manc­es of 2 ­tests for thyroglobulin (Tg) ­assays: the Dynotest Tg-Plus immu­nor­a­di­o­met­ric ­assay (­IRMA), a new meth­od ­that ­might be of inter­est for its ­claimed super­i­or sen­si­tiv­ity com­pared to oth­er meth­ods, and the ­HTGK-2 ­IRMA, one of the ­test cur­rent­ly ­used in clin­i­cal rou­tine.
Methods. The ­study was per­formed in ser­um sam­ples ­from 157 ­patients ­with dif­fer­en­tiat­ed thy­roid car­ci­no­ma (DTC). The clin­i­cal sen­si­tiv­ity of the ­test was eval­u­at­ed in ­patients ­with and with­out thy­roid stim­u­lat­ing hor­mone (TSH) sup­pres­sion.
Results. The low­est detect­able Tg con­cen­tra­tion val­ues and the with­in-­assay coef­fi­cient of vari­a­tion (CV) ­were 0.4 and 0.8 µg/L and 5% and 3% for the Dynotest Tg-Plus ­assay and the ­HTGK-2 ­assay, respec­tive­ly; the ­between-­assay CV was 6% for ­both ­assays. The clin­i­cal ­results of the Dynotest Tg-Plus and ­those of the ­HTGK-2 kit ­were sim­i­lar in ­both DTC ­patient pop­u­la­tions, ­either ­under or off the TSH sup­pres­sive treat­ment. In ­spite of the ­manufacturer’s state­ment ­that the cal­i­bra­tors of ­both ­assays had ­been stan­dard­ized ­against the ­same com­mon ref­er­ence (stan­dard CRM 457 of the Community Bureau of References), the Dynotest Tg-Plus ­test under­rat­ed by a fac­tor of 0.5 the Tg val­ues meas­ured by ­means of ­HTGK-2 ­IRMA.

language: English


FULL TEXT  REPRINTS

top of page